We have recently established and characterized cellular clones deriving from MDA-MB-231 breast cancer cells that express the human G D3 synthase (GD3S), the enzyme that controls the biosynthesis of b-and c-series gangliosides. The GD3S positive clones show a proliferative phenotype in the absence of serum or growth factors and an increased tumor growth in severe immunodeficient mice. This phenotype results from the constitutive activation of the receptor tyrosine kinase c-Met in spite of the absence of ligand and subsequent activation of mitogenactivated protein kinase/extracellular signal-regulated kinase and phosphoinositide 3-kinase/Akt pathways. Here, we show by mass spectrometry analysis of total glycosphingolipids that G D3 and G D2 are the main gangliosides expressed by the GD3S positive clones. Moreover, G D2 colocalized with c-Met at the plasma membrane and small interfering RNA silencing of the G M2 /G D2 synthase efficiently reduced the expression of G D2 as well as c-Met phosphorylation and reversed the proliferative phenotype. Competition assays using anti-G D2 monoclonal antibodies also inhibit proliferation and c-Met phosphorylation of GD3S positive clones in serum-free conditions. Altogether, these results demonstrate the involvement of the disialoganglioside G D2 in MDA-MB-231 cell proliferation via the constitutive activation of c-Met. The accumulation of G D2 in c-Met expressing cells could therefore reinforce the tumorigenicity and aggressiveness of breast cancer tumors.
Introduction
Gangliosides are glycosphingolipids (GSLs) carrying one or several sialic acid residues. They are essentially located on the outer leaflet of the plasma membrane in microdomains named "glycosynapses", where they can interact with transmembrane receptors or signal transducers involved in cell proliferation and signaling (Hakomori 2002; .
GSLs from ganglio-series are classified into four series according to the presence of 0-3 sialic acid residues linked to lactosylceramide (LacCer). The transfer of sialic acid is catalyzed in the Golgi apparatus by specific sialyltransferases [G M3 synthase (ST3Gal V), G D3 synthase (GD3S) and G T3 synthase (ST8Sia V), respectively] that show high specificity toward their glycolipid substrates (Zeng and Yu 2008) . LacCer, G M3 , G D3 and G T3 are therefore the precursors for 0-, a-, b-and c-series gangliosides (Figure 1 ), and the biosynthesis of these compounds determines the relative proportion of gangliosides in each series (Figure 1 ). Afterwards, further monosaccharides, including N-acetylgalactosamine (GalNAc), galactose (Gal) and sialic acid (N-acetylneuraminic acid, Neu5Ac), can be transferred in a stepwise manner by other specific glycosyltransferases (Tettamanti 2004) . The steady state level of membrane-associated gangliosides is therefore dependent on the activity of several glycosyltransferases, including ST3Gal V, ST8Sia I (GD3S), ST8Sia V or the β4GalNAc T1 (G M2 /G D2 synthase).
Normal human tissues mainly express a-series gangliosides (Figure 1 ), whereas complex gangliosides from b-and c-series are essentially found in developing tissues, during embryogenesis, and mainly restricted to the nervous system in healthy adults (Yamashita et al. 1999) . In mammals, the expression of b-and c-series gangliosides increases in pathological conditions including atherosclerosis, neurodegenerative disorders and cancer (Prokazova and Bergelson 1994; Birklé et al. 2003; Ariga et al. 2008) . In this context, G D3 and G D2 † The first two authors have equally participated to this work.
have been revealed as tumor-associated carbohydrate antigens in neuroectoderm-derived tumors such as melanoma, neuroblastoma and glioblastoma .
It has been clearly demonstrated that complex gangliosides play a key role in tumor growth and metastasis, by mediating cell proliferation, migration, adhesion and angiogenesis (Birklé et al. 2003) . Complex gangliosides have also been used as target molecules for cancer immunotherapy, such as G D3 in melanoma (Chapman et al. 2004; Scott et al. 2005; Lo et al. 2010) or G D2 in neuroblastoma (Navid et al. 2010; Yu et al. 2010) . However, the molecular functions of individual gangliosides in tumor progression and aggressiveness remain elusive. One mechanism by which gangliosides may exert their effects on proliferation is through the modulation of tyrosine kinase receptor (RTK) activation. For example, GD3S expression in rat pheochromocytoma PC12 cells leads to the cell surface accumulation of G D1b and G T1b , resulting in continuous neurotrophin receptor TrkA activation, enhancing cell growth without nerve growth factor binding (Fukumoto et al. 2000) . In A431 human epidermoid carcinoma cells, the activation of epithelial growth factor RTK (EGFR) is inhibited by G M3 through direct carbohydrate-carbohydrate interactions Fig. 1 . Biosynthesis of gangliosides. The action of ST3Gal V (G M3 synthase), ST8Sia I (G D3 synthase) and ST8Sia V (G T3 synthase) leads to the biosynthesis of the precursors of a-, b-and c-series gangliosides, respectively. The 0-series gangliosides are directly synthesized from LacCer. Elongation is performed by the sequential action of N-acetylgalactosaminyltransferase (β4GalNAc T1), galactosyltransferase (β3Gal T4) and sialyltransferases (ST3Gal I, ST3Gal II and ST8Sia V). Cer, ceramide; blue circle, Glc; yellow circle, Gal; yellow square, GalNAc; pink diamond, Neu5Ac.
G D2 -dependent activation of c-Met between G M3 and terminal GlcNAc residue on EGFR (Yoon et al. 2006; Kawashima et al. 2009 ).
In normal breast tissues, complex gangliosides are absent or expressed at very low level, but G D3 , 9-O-acetyl-G D3 and 9-O-acetyl-G T3 are oncofetal markers in invasive ductal breast carcinoma (Marquina et al. 1996) . Clinical studies have also shown that ST8SIA1, the gene encoding the GD3S, the key enzyme that controls b-and c-series gangliosides biosynthesis, displayed higher expression among estrogen receptor (ER) negative breast cancer tumors (Ruckhäberle et al. 2008) . Furthermore, ST8SIA1 expression was associated with a higher histological grade in ER negative tumors (Ruckhäberle et al. 2009 ).
We have recently developed a cellular model deriving from the triple negative (ER−, PR− and Her2−) MDA-MB-231 breast cancer cell line, expressing the human GD3S and showing a proliferative phenotype in the absence of serum or exogenous growth factors (Cazet et al. 2009 ). The proliferative capacities of MDA-MB-231 GD3S + clones in serum-free conditions directly proceed from the constitutive activation of the c-Met receptor (Peschard and Park 2007) and downstream mitogen-activated protein kinase (MEK)/extracellular signalregulated kinase (ERK) and phosphoinositide-3 kinase (PI3K)/Akt signaling pathways (Cazet et al. 2010) . Moreover, GD3S expression not only promotes cell growth in vitro but also stimulates primary tumor growth in severe combined immunodeficiency mice. Finally, micro-array analysis has shown a higher expression of ST8SIA1 and MET in the basal-like subtype (Sorlie et al. 2003) of human breast tumors (Cazet et al. 2010) .
In the present study, we show that G D3 and G D2 are the main gangliosides expressed by MDA-MB-231 GD3S + clones, whereas control MDA-MB-231 cells accumulate mainly G M3 and G M2 . We also demonstrate that G D2 is directly involved in the constitutive activation of c-Met in the absence of the ligand hepatocyte growth factor (HGF)/scatter factor, probably through specific interaction between the c-Met receptor and the oligosaccharide moiety of G D2 .
Results

Ganglioside contents of GD3S
+ MDA-MB-231 cells
To precisely establish the ganglioside profile of GD3S + MDA-MB-231 cells, we analyzed the composition of GSL by MALDI-TOF mass spectrometry after permethylation ( Figure 2 , Table I ). Two ceramide isoforms are commonly expressed in human tissues due to the substitution of the sphingosine moiety by palmitic acid C16:0 or lignoceric acid C24:0 ( Figure 2 , Table I ). As expected, wild-type or empty vector-transfected MDA-MB-231 (control) cells only expressed a-series gangliosides, mainly G M3 and G M2 (Figure 2A and B). HPTLC analysis confirmed that wild-type MDA-MB-231 cells only expressed a-series gangliosides, mainly G M3 and G M2 , G M1 being expressed at a low level (Figure 3 , lanes A5 and B5). Glucosylceramide and LacCer were also detected, as well as globo-series GSLs G b3 and G b4 . On the other hand, both GD3S + clones (clones 4 and 11) accumulated b-and c-series gangliosides, as it was previously shown by flow cytometry and confocal microscopy using different anti-ganglioside mAbs (Cazet et al. 2009 ). G D3 and G D2 represent the most predominant complex gangliosides, whereas lower amount of G D1b , G T3 and G T2 were detected ( Figure 2C and D) . These results fit well with the high expression of the β4GalNAc T1 in MDA-MB-231 cells, as previously shown by QPCR (Cazet et al. 2009 ). In parallel, G M3 and G M2 expression levels were reduced in MDA-MB-231 GD3S + cells compared with control cells. Similarly, HPTLC analysis confirmed that both GD3S + clones mainly expressed G D3 and G D2 (Figure 3, lanes A4 and B4) . Moreover, immunostaining using the A2B5 mAb allows also to detect G T3 and G T2 in GD3S + clones, which cannot be distinguished from G D1b and G T1b on the resorcinol stained HPTLC plate (Figure 3, lane B6) . The structures of individual GSLs were confirmed by mass spectrometry fragmentation analyses by MALDI-TOF/TOF (data not shown). Finally, we were able to show by immunocytochemistry and confocal microscopy the colocalization of G D2 and c-Met at the plasma membrane of GD3S + clones (Figure 4 ).
SiRNA inhibition of β4GalNAc T1 expression strongly reduces c-Met activation and reverses the proliferative phenotype of GD3S + cells
In order to determine the role of G D2 in the activation of c-Met and proliferative phenotype, the G M2 /G D2 synthase (β4GalNAc T1) expression was inhibited in GD3S + cells with siRNA sequences. The ability of the siRNA to specifically silence the B4GALNACT1 gene was evaluated by QPCR and flow cytometry analysis. In comparison with control siRNA, the silencing of the G M2 /G D2 synthase resulted in 90, 87 and 90% decreases of relative β4GalNAc T1 mRNA expression in MDA-MB-231 control, clone 4 and clone 11, respectively ( Figure 5A ). In parallel, siRNA efficiently reduced the expression of G D2 in the both clones, whereas G D3 and G T3 expression were increased ( Figure 5B ). As shown in Figure 6A , silencing of G M2 /G D2 synthase decreased proliferation of both GD3S + clones during the first 3 days of culture, demonstrating the involvement of GalNAc-substituted complex gangliosides, mainly G D2 , in GD3S + cells proliferation in deprivation conditions. The phosphorylation status of 42 RTKs was simultaneously examined in MDA-MB-231 GD3S + cells 24 h after transfection with corresponding siRNA using phospho-RTK arrays. As previously described (Cazet et al. 2010 ), GD3S + MDA-MB-231 cells displayed a strong phosphorylation of the c-Met receptor (coordinates c3, c4) in control conditions ( Figure 6B ). The phosphorylation of EGFR (coordinates d1, d2) and of the receptor for angiopoietins Tie-2 (coordinates b1, b2) is also observed. In parallel, inhibition of G M2 /G D2 synthase expression strongly decreased the c-Met phosphorylation compared with MDA-MB-231 GD3S + cells transfected with control siRNA. A similar decrease in Tie-2 (coordinates b1, b2) and a slight decrease in EGFR (coordinates d1, d2) phosphorylation were also observed ( Figure 6B ). Even if siRNA treatment strongly inhibited β4GalNAc T1 mRNA expression ( Figure 5A ), a slight activation of c-Met remained detectable on phospho-RTK arrays ( Figure 6B ). This could explain why the growth rate of siRNA GD3S + -treated cells is not completely reduced to the control level.
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Fig. 2. MALDI-TOF analysis of permethylated GSLs isolated from MDA-MB-231 GD3S + cells. Permethylated GSLs isolated from (A) wild-type MDA-MB-231, (B) control MDA-MB-231 transfected with empty vector, (C) GD3S
+ MDA-MB-231 clone 4 and (D) clone 11 were analyzed by MALDI-TOF mass spectrometry. Gangliosides from b-or c-series were not detected in wild-type and control cells, whereas complex gangliosides containing 2-3 sialic acid residues (i.e. G D3 , G D2 , G T3 , G T2 ) were detected in MDA-MB-231 GD3S + cells. Black circle, Glc; gray circle, Gal; gray square, GalNAc; dark gray diamond, Neu5Ac;
, Ceramide either N-palmitoyl-sphingosine or N-lignoceryl-sphingosine. Only masses corresponding to N-palmitoyl-(C16:0) or N-lignoceroyl-(C24:0) 2-amino-4-octadecene-1,3-diol (sphingosine) are indicated. Assignments were confirmed by mass spectrometry fragmentation of permethylated glycolipids by MALDI-TOF/TOF (data not shown). WT, non-transfected cells; control, cells transfected with empty vector; clones 4 and 11, cells transfected with human GD3S cDNA; LacCer, lactosylceramide; GlcCer, glucosylceramide; Gb, globoside.
G D2 -dependent activation of c-Met
Inhibition of cell growth and c-Met activation by the anti-G D2 mAb Effect of the anti-G D2 mAb on cell proliferation was then analyzed by adding affinity purified specific mAbs to the culture medium. The high proliferative capacity of the MDA-MB-231 GD3S + was strongly decreased in the presence of the anti-G D2 4G2 mAb, whereas the anti-G D3 4F6 mAb has no significant effect on cell proliferation. The inhibition effect of anti-G D2 was dependent on the mAb concentration and became significant even at 15 µg/mL ( Figure 7A ). In parallel, no morphological change was observed in GD3S + clones after anti-G D2 mAb treatment (data not shown) and the anti-G D2 mAb has no effect on the cellular level of G D2 (Supplementary data). Finally, as shown in Figure 7B , the anti-G D2 mAb also strongly decreased the phosphorylation of c-Met, whereas anti-G D3 had no effect.
Discussion
The pharmacological and genetic control of gangliosides expression has been applied during the past years to study the influence of b-series gangliosides on cell behavior, including cell proliferation, and accumulating evidences indicate the tumor-specific and malignant phenotype-associated expression of G D2 . For example, G D2 expression is required and sufficient to drive human small cell lung cancer (SCLC) proliferation, migration and invasion in vitro as well as tumor growth (Ko et al. 2006) . In this context, the disialoganglioside G D2 represents a valid therapeutic target for cancer immunotherapy (Ragupathi et al. 2003; Yvon et al. 2009; Lo et al. 2010) .
Growth factor receptors are characterized by a common susceptibility to gangliosides, which modulate the receptorassociated tyrosine kinase activity in glycosynaptic microdomains (Miljan and Bremer 2002; Kaucic et al. 2006 ). Studies (Hyuga et al. 2001) . G M3 and G M2 can form heterodimers that specifically interact with tetraspanin family member CD82, and G M3 /G M2 /CD82 complexes inhibit c-Met activation and cross-talk with integrins, providing a basis for the control of cell proliferation and invasiveness (Todeschini et al. 2007 . In parallel, we have demonstrated that the expression of GD3S and complex gangliosides in MDA-MB-231 cells lead to a proliferative phenotype by a positive regulation of c-Met phosphorylation and subsequent signal transduction MEK/ERK and PI3K/Akt pathways (Cazet et al. 2010) . Moreover, the proliferative phenotype of GD3S + cells was due to a HGF-independent activation of c-Met. Thus, c-Met is activated in the absence of HGF and 5D5 Fab, which inhibits HGF-Met association and ligand-dependent activation, does not affect Met activation (Cazet et al. 2010) . The reduction in a-series ganglioside levels cannot therefore explained c-Met activation, indicating that the HGF-independent activation of c-Met in GD3S + MDA-MB-231 cells is induced by b-series gangliosides. Consequently, these studies seem to indicate that the ganglioside-dependent regulation of c-Met is related to ganglioside sialylation status, a-series inhibiting c-Met phosphorylation, whereas b-or c-series gangliosides strongly activate the receptor in a ligand-independent manner.
Here, we show by mass spectrometry and HPTLC analysis of total GSLs that G D2 is the main ganglioside expressed by MDA-MB-231 GD3S + cells. SiRNAs silencing of the G M2 / G D2 synthase reversed the proliferative phenotype due to the strong decrease in c-Met phosphorylation. Accumulation of band c-series ganglioside precursors, G D3 and G T3 , respectively, has no effect on c-Met activation. Altogether, these results show that G D2 contributes to the constitutive activation of the c-Met axis, independently on HGF binding, leading to enhanced signaling, as observed in the basal-like subtype of breast cancer (Graveel et al. 2009; Ponzo et al. 2009 ).
Although the interactions between G D2 and c-Met remain to be demonstrated, the inhibition of cell proliferation by the anti-G D2 mAb clearly indicates the role of the oligosaccharide moiety of G D2 in c-Met activation. G D2 -dependent c-Met activation might be achieved by the control of tyrosine kinase activity by a direct binding through carbohydrate-carbohydrate interactions between G D2 and N-glycosylated chains of the receptor, as it has been previously demonstrated for the EGFR (Yoon et al. 2006; Kawashima et al. 2009 ). On the other hand, the G D2 -induced c-Met constitutive activation could be also dependent on a cross-talk between G D2 , c-Met and other signaling molecules. Such complexes have been reported to modulate RTK activity (Todeschini et al. 2007 Park et al. 2009 ). Cross-communication between integrins and RTKs is thought to be required for maximal activation of the Ras-mitogen-activated protein kinase (MAPK) signal transduction pathway that drives cell proliferation. In parallel, the importance of ganglioside composition in defining integrin function is also well-documented Wang et al. 2001 Wang et al. , 2002 . G D2 physically interacts with integrin and focal adhesion kinase (FAK) to activate the downstream signaling pathway MEK/ERK, playing pivotal role on cell proliferation and malignant properties of SCLC (Yoshida et al. 2001; Aixinjueluo et al. 2005) . In this context, the proliferative phenotype of MDA-MB-231 GD3S + cells could be due to the formation of a tertiary complex consisting of G D2 , integrins and c-Met, which could contribute to the constitutive trans-phosphorylation of the receptor and reinforce the malignant properties of the cells. Eventual interactions between disialoganglioside G D2 and integrins should be clarified using G D2 -dependent activation of c-Met different approaches, such as co-immunoprecipitation, crosslinking and confocal microscopy, to further understand the mechanism of specific c-Met activation.
Interestingly, incubation with the anti-G D2 mAb seems to induce cell death of MDA-MB-231 GD3S + cells after 4 days of culture in deprivation conditions (data not shown). Molecular mechanisms inducing the cell death of cancer cells by the anti-G D2 mAb were investigated previously. Treatment of M21 melanoma cells with the anti-G D2 mAb causes cell rounding and detachment from a fibronectin substrate (Cheresh and Klier 1986) . Furthermore, G D2 -positive lung cancer cells treated with the anti-G D2 mAb undergo anoikis through the conformational changes of integrin molecules, subsequent FAK dephosphorylation and p38/MAPK activation (Aixinjueluo et al. 2005) . The mechanism of cell death induction needs to be clarified in MDA-MB-231 GD3S + cells but should provide new insights toward immunotherapy application in the drug-resistant breast cancer basal-like subtype.
In conclusion, by using a cellular model that mimic the in vivo situation that could occur in the basal-like subtype of breast cancer tumors expressing the GD3S, we have demonstrated that the oligosaccharide moiety of G D2 specifically activates c-Met and subsequent transduction pathways, enhancing the oncogenic effect of the c-Met receptor. This underlies the need to develop such cellular models and sheds light on the effect of ganglioside expression on breast cancer cell signaling.
Material and methods
Antibodies and reagents
Anti-G D3 R24 monoclonal antibody (mAb; Pukel et al. 1982) was purchased from Abcam (Paris, France) and anti-G D2 S220-51 mAb from Seikagaku Corp. (Tokyo, Japan). Anti-G D3 4F6, anti-G D2 4G2 (Portoukalian et al. 1993 ) and anti-G T3 A2B5 (Dubois et al. 1990 ) mAbs were kindly provided by Prof. Jacques Portoukalian (Department of + clones proliferation in serum-free conditions. One day after transfection, cells were seeded in 96-well plates and cultured during 5 days in serum-free medium as described in Materials and Methods section. Cell growth was analyzed by MTS assay. Counting was performed in 16 wells and data are the mean of three independent manipulations. **P < 0.01, GD3S + vs. control. (B) Phospho-array analysis. Total cell lysates from control, GD3S + clone 4 and clone 11, transfected with specific siRNA-targeting B4GALNACT1 or with a control sequence, were subjected to phospho-RTK array. Phospho-RTK array coordinates are given on the left side of the figure. Black dots represent Phospho-Tyrosine positive control; a1, a2: EphA6; a3, a4: EphA7; a5, a6: EphB1; a7, a8: EphB2; a9, a10: EphB4; a11, a12: EphB6; a13, a14: Mouse IgG1 negative control; a15, a16: Mouse IgG2A negative control; a17, a18: Mouse IgG2B negative control; a19, a20: Goat IgG negative control; a21, a22: PBS negative control; b1, b2: b3, b4: TrkA; b5, b6: TrkB; b7, b8: TrkC; b9, b10: VEGFR1; b11, b12: VEGFR2; b13, b14: VEGFR3; b15, b16: MuSK; b17, b18: EphA1; b19, b20: EphA2; b21, b22: EphA3; b23, b24: EphA4; c1, c2: Mer; c3, c5, c6: MSPR; c7, c8: PDGFRα; c9, c10: PDGFRβ; c11, c12: SCFR; c13, c15, c17, c19, c20: ROR1; c21, c22: ROR2; c23, d1, d2: EGFR; d3, d4: ErbB2; d5, d6: ErbB3; d7, d8: ErbB4; d9, d10: FGFR1; d11, d12: FGFR2α; d13, d14: FGFR3; d15, d16: FGFR4; d17, d18 : Insulin R; d19, d20: IGF-I R; d21, d22: Axl; d23, d24: Dtk.
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Transplantation and Clinical Immunology, Claude Bernard University and Edouard Herriot Hospital, Lyon, France). The 4F6 and 4G2 mAbs were purified from conditioned culture media by affinity chromatography on protein G column (Sigma-Aldrich, Lyon, France), and protein concentration was determined by the Bio-Rad RC protein assay kit II (Bio-Rad, Marnes-la-Coquette, France). Anti-β-actin, mouse mAb against the COOH-terminal region of human Met and rabbit polyclonal Ab against phosphorylated tyrosines 1234 and 1235 of the Met kinase domain were purchased from Cell Signaling Technology (Saint-Quentin-en-Yvelines, France). Goat anti-c-Met affinity purified polyclonal immunoglobulin G (IgG) AF276 was from R&D Systems Europe (Lille, France). Anti-rabbit and anti-mouse IgG conjugated with horseradish peroxidase, and fluorescein isothiocyanate (FITC)-conjugated sheep anti-mouse IgG was purchased from GE Healthcare (Templemars, France). FITC-conjugated rabbit anti-mouse IgM and Alexa Fluor® 647 chicken anti-goat IgG were purchased from Molecular Probes (Invitrogen, Cergy-Pontoise, France). FITC-conjugated goat anti-mouse IgG was from Sigma-Aldrich. Small interfering RNAs (siRNAs) were manufactured by Dharmacon (Thermo Scientific, Illkirch, France) and quantitative real-time polymerase chain reaction (QPCR) primers were synthesized by Eurogentec (Seraing, Belgium).
Cell culture
Cell culture reagents were purchased from Lonza (Levallois-Perret, France). The breast cancer cell line MDA-MB-231 was obtained from the American Type Cell Culture Collection (Rockville, MD). Cells were routinely grown in monolayers and maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/mL of penicillin-streptomycin, at 37°C in 5% CO 2 . MDA-MB-231 control (empty vector transfected) and MDA-MB-231 GD3S + clones 4 and 11 were obtained as previously described (Cazet et al. 2009 ) and cultured in the presence of 1 mg/mL of G418 (Invitrogen).
Extraction and preparation of glycolipids Twenty dishes (10 cm diameter) of cultured cells were washed twice with ice-cold phosphate-buffered saline (PBS) and cells were scraped and homogenized. Cells were suspended in 200 µL of water and sonicated on ice. The resulting material was dried under vacuum and sequentially extracted by CHCl 3 / CH 3 OH (2:1, v/v), CHCl 3 /CH 3 OH (1:1, v/v) and CHCl 3 / CH 3 OH/H 2 O (1:2:0.8, v/v/v). Supernatants were pooled, dried and subjected to a mild saponification in 0.1 M NaOH in CHCl 3 /CH 3 OH (1:1) at 37°C for 2 h and then evaporated to dryness (Schnaar 1994) . Samples were reconstituted in CH 3 OH/H 2 O (1:1, v/v) and applied to a C 18 Sep-Pak cartridge (Waters, Milford, MA) equilibrated in the same solvent system. After washing with five volumes of CH 3 OH/H 2 O (1:1, v/v), GSLs were eluted by two volumes of CH 3 OH, two volumes of CHCl 3 /CH 3 OH (1:1, v/v) and two volumes of CHCl 3 /CH 3 OH (2:1, v/v).
Mass spectrometry analysis of GSLs
Prior to mass spectrometry analysis, GSLs were permethylated according to Ciucanu and Kerek (1984) . Briefly, compounds were incubated 2 h in a suspension of 200 mg/mL of NaOH in dry dimethyl sulfoxide (300 µL) and ICH 3 (200 µL). The methylated derivatives were extracted in CHCl 3 and washed several times with water. The reagents were evaporated and the sample was dissolved in CHCl 3 in the appropriate dilution. Mass spectrometry analysis of permethylated GSLs was performed by matrix-assisted laser desorption-ionization (MALDI) time-of-flight (TOF) on a Voyager Elite reflectron mass spectrometer (PerSeptive Biosystems, Framingham, MA), equipped with a 337-nm UV laser. Samples were prepared by mixing on a tube 5 µL of diluted permethylated derivatives solution in CHCl 3 and 5 µL of 2,5-dihydroxybenzoic acid matrix solution [10 mg/mL dissolved in CHCl 3 /CH 3 OH (1:1, v/v)]. The mixtures (2 µL) were then spotted on the target plate and air-dried.
Thin-layer chromatography analysis of gangliosides Standard gangliosides were purified from human melanoma tumors (Portoukalian et al. 1979 ) and separated into two fractions, one with G M3 and G D3 and the second with the more + clones were treated for 6 h with 30 µg/mL of the 4G2 mAb and then used for an immunoblotting with a specific anti-phospho-Met or an anti-Met antibody as described in Materials and methods section. The anti-G D3 4F6 mAb and an irrelevant mAb were used as a control.
G D2 -dependent activation of c-Met complex gangliosides. Bovine brain gangliosides were from Sigma-Aldrich. The gangliosides were applied onto highperformance thin-layer chromatography (HPTLC) glass plates (WWR, Paris, France) and migrated in CHCl 3 /CH 3 OH/0.2% CaCl 2 (55:45:10, v/v/v) . The gangliosides spots were visualized with the resorcinol/HCl spray reagent (Svennerholm 1963 ) 5 min at 150°C. Immunostaining was carried out using an A2B5 mAb to detect polysialogangliosides (Dubois et al. 1990 ). Standards and gangliosides of clone 11 were migrated on an aluminum-backed HPTLC plate in the same solvent system as above and processed as described (Portoukalian and Bouchon 1986) .
Immunofluorescence staining MDA-MB-231 cells were plated on glass coverslips in 6-well plates (1.6 × 10 4 cells/well). The next day, cells were washed and fixed 30 min in 4% paraformaldehyde at room temperature. After washing, cells were blocked in PBS/5% bovine serum albumin (BSA; Sigma-Aldrich) for 1 h. Primary antibodies (goat anti-c-Met AF276, mouse anti-G D2 S220-51 or both) were incubated for 1 h. The cells were washed with PBS and incubated 1 h with a combination of secondary antibodies (red-fluorescent Alexa Fluor® 647-conjugated antigoat IgG and green-fluorescent FITC-conjugated anti-mouse IgG). Cells were then washed with PBS and the nuclei counterstained with Hoechst 33258. Coverslips were mounted with Glycergel mounting medium (Dako, Carpenteria, CA). Fluorescence was examined in oil immersion at 21°C. For confocal fluorescence microscopy, slides were observed in an LSM 710 Laser Scanning Microscope (Carl Zeiss, Thornwood, NY), numerical aperture PLAN-APOCHROMAT 63× NA 1.4 with the ZEN acquisition software.
RNA interference assays
Cells were transfected with 200 nM duplexes siRNA-targeting B4GALNACT1 (L-011279-00) or a scramble sequence using Lipofectamine 2000 reagent (Invitrogen) following the manufacturer's instructions with slight modifications. Cells were transfected in OptiMEM medium, in the absence of FBS. Two cycles of siRNA were done to achieve maximal knockdown. Cells were transfected twice with corresponding siRNAs at t = 0 h and t = 48 h and were collected 24 h later for QPCR, cell growth and phospho-array assays, and 48 h later for flow cytometry analysis.
Reverse transcription and QPCR Total RNA was extracted using the Nucleospin RNA II (Macherey-Nagel, Hoerdt, France) according to the protocol provided by the manufacturer. Total RNA (1 µg) was reverse transcribed using first-strand cDNA synthesis kit (Amersham Biosciences, Freiburg, Germany). QPCR and subsequent analysis were performed using the Mx-3005P Quantitative System (Stratagene, Amsterdam, the Netherlands). Primer pairs for B4GALNACT1 and HPRT (hypoxanthine phosphoribosyltransferase) transcripts were described previously (Cazet et al. 2009 ). QPCRs (25 µL) were performed using 2× SYBR® Green Universal QPCR Master Mix (Stratagene) with 2 µL of 1:5 cDNA dilution and 300 nM final concentration of each primer. QPCR conditions were as follows: 95°C for 30 s, 51°C for 45 s, 72°C for 30 s (40 cycles). Quantification was performed by the method described by Livak and Schmittgen (2001) . Serial dilutions of the appropriate positive control cDNA sample were used to create standard curves for relative quantification and B4GALNACT1 transcripts were normalized to HPRT expression. Assays were performed in triplicate and QPCR amplification was repeated three times. Negative control reactions were performed by replacing cDNA templates by sterile water or corresponding total RNA samples.
Flow cytometry analysis
Cells were detached by 4 mM ethylenediaminetetraacetic acid (EDTA) in PBS and incubated for 1 h at 4°C with antigangliosides mAbs: anti-G D3 R24 (1:100), anti-G D2 S220-51 (1:75) and anti-G T3 A2B5 (1:10), diluted in PBS containing 0.5% BSA. After washing with PBS/0.5% BSA, cells were incubated for 1 h on ice with FITC-conjugated anti-mouse IgM or IgG. Controls were performed using appropriate isotype, as well as secondary antibodies alone. Cells were then subjected to flow cytometry analysis using a FACScalibur flow cytometer from Becton Dickinson (Le-Pont-de-Claix, France).
Proliferation assays
Cell growth was analyzed using MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] reagent (Promega, Charbonnières-les-Bains, France) according to the manufacturer's procedure. For RNA interference assay, 2 × 10 3 cells were seeded in 96-well plates (Thermo Fisher Scientifics, Langenselbold, Germany) after two cycles of siRNA and then cultured during 5 days in DMEM serum-free medium. Cell numbers were determined after 1, 2, 3, 4 and 5 days by adding MTS to the wells 2 h before spectrophotometric reading (absorbance at 490 nm).
For cell growth inhibition assay, transfectant cells and control cells (2.5 × 10 3 ) were seeded in 96-well plates and grown in DMEM culture medium containing 0.1% FBS. After 12 h, the medium was replaced and cells were treated for 4 days with the anti-G D2 4G2 mAb, anti-G D3 4F6 mAb or with an irrelevant mAb diluted to the indicated concentrations.
Phospho-RTK array analysis
Two days after transfection with siRNA, cells were lysed in NP-40 lysis buffer [1% NP-40, 20 mM Tris-HCl ( pH 8.0), 137 mM NaCl, 10% glycerol, 2 mM EDTA, 1 mM sodium orthovanadate and protease inhibitor cocktail tablet (Roche, Meylan, France)]. The human Phospho-RTK array kit (R&D Systems Europe) was used according to the manufacturer's protocol. Briefly, the arrays were blocked in the appropriate blocking buffer and incubated overnight at 4°C with 200 µg of total protein extract. The arrays were washed three times and incubated with a horseradish peroxidase-conjugated phospho-tyrosine detection antibody, 1 h at room temperature, before treated with ECL-Plus Western Blotting Detection A Cazet et al. Reagent (GE Healthcare) and exposed to Kodak film (GE Healthcare).
Immunoblotting
Transfectant cells and control cells (3 × 10
5 ) were seeded in 6-well plates and grown in DMEM containing 0.1% FBS. The next day, the medium was replaced and cells were treated for 6 h with 30 µg/mL of the anti-G D2 4G2 mAb, anti-G D3 4F6 mAb or with an irrelevant mAb as a control. Cells were harvested by scraping in PBS and subjected to centrifugation (10,000 × g, 10 min). The pellets were then resuspended in lysis buffer [25 mM Tris-HCl ( pH 7.4), 10 mM EDTA, 15% glycerol, 0.1% Triton X-100, protease inhibitor tablet (Roche) and phosphatase inhibitor cocktails 2 and 3 (Sigma-Aldrich)]. The supernatants were assessed for protein concentration using the Bio-Rad RC protein assay kit II. For the phospho-Met and Met detection, 30 µg of total proteins from each cell lysate was subjected to sodium dodecyl sulfatepolyacrylamide gel electrophoresis and transferred onto a polyvinylidene fluoride membrane (Millipore, Molsheim, France). Membranes were then incubated overnight at 4°C with the primary antibody, incubated at room temperature for 1 h with a horseradish peroxidase-conjugated anti-mouse or anti-rabbit secondary antibody. Analysis was done by chemiluminescence using the ECL-Plus western blotting detection reagent (GE Healthcare) with Kodak film.
Statistical analyses
Student's t-test was used for statistical analysis. P < 0.05 was considered as statistically significant.
Supplementary data
Supplementary data for this article is available online at http://glycob.oxfordjournals.org/. 
